New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2014
06:35 EDTATIAllegheny Technologies upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse upgraded Alleghany due to recent share weakness, limited downside, improved liquidity, and upcoming positive free cash flow. Price target raised to $41 from $34.
News For ATI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2015
14:10 EDTATIAllegheny Technologies downgraded to Neutral from Buy at BofA/Merrill
Subscribe for More Information
13:32 EDTATIAllegheny Technologies weakness a buying opportunity, says Stifel
07:19 EDTATIAllegheny Technologies sees FY15 capex roughly $250M
ďOur balance sheet remains solid, with cash on hand of $251M at the end of the second quarter 2015 and no borrowings outstanding under our $400M domestic borrowing facility. Total debt to total capitalization of 37.0% at the end of the second quarter 2015 was unchanged from year-end 2014. Including expected payments associated with the HRPF project, we now expect 2015 capital expenditures to be approximately $250M, of which $63M has been spent in the first six months of 2015.Ē
07:16 EDTATIAllegheny Technologies reports Q2 EPS (15c), consensus 4c
Subscribe for More Information
July 20, 2015
15:11 EDTATIAllegheny Technologies technical notes before earnings
Subscribe for More Information
July 15, 2015
16:28 EDTATIOn The Fly: Top stock stories for Wednesday
Subscribe for More Information
12:18 EDTATIOn The Fly: Top stock stories at midday
Subscribe for More Information
12:02 EDTATIAllegheny Technologies dives after slashing Q2 outlook, peers follow
Subscribe for More Information
July 14, 2015
19:05 EDTATIOn The Fly: Pre-market Movers
UP AFTER EARNINGS: CSX (CSX), up 3.5%. ALSO HIGHER: Receptos (RCPT), up 10.2% following deal to be acquired by Celgene (CELG)... Celgene is up 5.8% after announcing acquisition of Receptos... Celsion (CLSN), up 8.8% after being initiated with a Buy at BTIG... Aratana Therapeutics (PETX), up 10% after results of pivotal study of AT-003. DOWN AFTER EARNINGS: Peregrine (PPHM), down 3%... Yum! Brands (YUM), down marginally. ALSO LOWER: Allegheny Technologies (ATI), down 9.3% after providing second quarter EPS guidance... Mead Johnson (MJN), down 4.8% after reducing fiscal 2015 EPS guidance.
16:18 EDTATIAllegheny Technologies sees Q2 EPS (17c)-(15c), consensus 20c
Allegheny Technologies commented that, due primarily to challenging business conditions in its Flat Rolled Products business and further weakening in demand from the oil and gas market, it expects to report a net loss attributable to ATI of $16 to $18M, or $(0.15) to $(0.17) per share, for the second quarter 2015. ATI said its second quarter performance continued to be pressured by the ATI Flat Rolled Products segment, which recorded its sixth quarterly operating loss over the last eight quarters. Base-selling prices for standard stainless steel sheet products fell throughout the second quarter due primarily to a record surge of low-priced imports, primarily from China, and aggressive inventory reductions by distribution customers. In addition, product margins were pressured as raw material surcharges fell throughout the second quarter primarily due to lower prices for nickel units. Shipments of standard stainless products fell significantly, compared to the first quarter 2015, as many customers reduced inventories throughout the quarter as base-selling prices and raw materials surcharges fell. In the High Performance Materials and Components segment, demand for ATIís specialty materials in the second quarter from the oil and gas market was much lower than expected. Demand for ATIís specialty materials used in exploration applications and for forged products used in drilling and flow equipment applications was much weaker than during the first quarter 2015. In addition, second quarter shipments of titanium mill products to the airframe market had a less favorable product mix.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use